Natco Pharma: PAT growth of 59% & Revenue…

Aug 19, 2024

FY25 PAT growth of 20%. Guiding for 15-20% revenue growth in FY25. Possibility of inorganic growth coming in FY26. Reasonable valuations based on free cash flow yield.

Read →

Comments

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts

Money Muscle

Natco Pharma: PAT growth of 59% & Revenue…